ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

globe_newswire · 2026-10-23 · Bullish AI sentiment

$ADC $ARR

NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety and efficacy data from the Phase 1 (NCT07066657) study of CDH17-targeted ADC ARR-217 (MRG007) in patients with gastrointestinal cancers, will be presented in a rapid oral presentation at the European Society for Medical Oncolo

Sector coverage: Real Estate · REIT - Retail · REIT - Mortgage

Read the original at globe_newswire ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.